Biblio
Validation of the imatinib-therapy failure model. Leukemia. 2023.
RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.
Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.
Novel ZFPL1::NUP98 fusion gene identified in an adult acute myeloid leukemia patient. Int J Lab Hematol. 2024.
. A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML. Blood Adv. 2024.
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discov Oncol. 2024;15(1):78.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Comparison of two different rabbit antithymocyte globulin (r-ATG) preparations:Thymocyte r-ATG versus T lymphoblast cell line r-ATG in allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: propensity score-matched analysi. Biol Blood Marrow Transplant. 2020.
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.
A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. Hematology. 2021;26(1):741-750.
Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations. Hematology. 2022;27(1):1184-1190.
.